Questions on Valeda for AMD: Clinical Results

Regarding results using Valeda Photobiomodulation for dry AMD, we can look to the LIGHTSITE III study which led to FDA authorization. In that study, at 21 months, 61.5 percent of patients improved one line of vision or more, 23.1 percent improved two lines of vision or more and 4.4 percent improved three lines of vision or more. Stated differently, 89 percent of patients improved by at least one line of vision.